Low-dose decitabine priming endows CAR T cells with enhanced and persistent anti-tumor potential by epigenetic reprogramming in vivo and in vitro

ABSTRACT: Low-dose decitabine priming endows CAR T cells with enhanced and persistent anti-tumor potential by epigenetic reprogramming in vivo and in vitro

PROVIDER: PRJNA657045 | ENA |

REPOSITORIES: ENA